Windtree Therapeutics (WINT) Misses Q1 EPS by 12c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. NDAQ

Go back to Windtree Therapeutics (WINT) Misses Q1 EPS by 12c

Windtree Therapeutics Reports First Quarter 2016 Financial Results and Provides Business Updates

May 12, 2016 7:00 AM EDT

WARRINGTON, Pa., May 12, 2016 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today reported financial results for the first quarter ended March 31, 2016 and provided key business updates. The Company will also host a conference call today at 8:00 a.m. EDT.

Key Business and Financial Updates

Recently achieved an important milestone in the AEROSURF® phase 2b clinical trial in respiratory distress syndrome (RDS) with the initiation of sites and enrollment at selected clinical sites in... More